Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Antibody–drug conjugates (ADCs) are being actively pursued as a treatment option for cancer following the regulatory approval of brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla). ADCs consist of a cytotoxic agent conjugated to a targeting antibody through a linker. The two appr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioconjugate chemistry 2017-05, Vol.28 (5), p.1371-1381
Hauptverfasser:	Sun, Xiuxia, Ponte, Jose F, Yoder, Nicholas C, Laleau, Rassol, Coccia, Jennifer, Lanieri, Leanne, Qiu, Qifeng, Wu, Rui, Hong, Erica, Bogalhas, Megan, Wang, Lintao, Dong, Ling, Setiady, Yulius, Maloney, Erin K, Ab, Olga, Zhang, Xiaoyan, Pinkas, Jan, Keating, Thomas A, Chari, Ravi, Erickson, Hans K, Lambert, John M
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - immunology Antigens Antineoplastic Agents, Phytogenic - pharmacokinetics Antineoplastic Agents, Phytogenic - pharmacology Biochemical characteristics Biochemistry Cancer Conjugates Cytotoxic agents Cytotoxicity Dosage Drugs Effectiveness Effects Epidermal growth factor Epidermal growth factor receptors Female Folic acid Humans Immunoconjugates - pharmacokinetics Immunoconjugates - pharmacology In vitro methods and tests KB Cells Kinetics Liver Localization Lysine Maytansine - pharmacokinetics Maytansine - pharmacology Mice Monoclonal antibodies Pharmacokinetics Pharmacology Stability analysis Targeted cancer therapy Tissue Distribution Trastuzumab Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!